共 42 条
[3]
Aldeyra Therapeutics Inc, The GUARD Trial-Part 1: A phase 3 clinical trial of repeated intravitreal injections of ADX- 2191 versus standard-of-care for prevention of proliferative vitreoretinopathy
[5]
Bach M, 2007, Invest Ophthalmol Vis Sci